Head & neck · 2025
Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sanomachi Tomomi, Shimoi Tatsunori, Kojima Yuki, Takahashi Hideaki, Arakaki Motoko, Kawachi Asuka, Okuma Hitomi Sumiyoshi, Hoshino Mai, Ito Munehiro, Saito Ayumi, Kita Shosuke, Maejima Aiko, Nishikawa Tadaaki, Sudo Kazuki, Mori Taisuke, Fujiwara Yasuhiro, Yonemori Kan
Аннотация
BACKGROUND: Adenoid cystic carcinoma (ACC) is the second most common and treatment-resistant salivary gland carcinoma (SGC). Although platinum-based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after platinum therapy remains unclear.
METHODS: We retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum-based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin.
RESULTS: The median age was 61 years. 84% achieved disease control with the first-line or later platinum-based therapy (median progression-free survival [mPFS]: 7.6 months). Second-line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable.
CONCLUSION: Eribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.
METHODS: We retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum-based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin.
RESULTS: The median age was 61 years. 84% achieved disease control with the first-line or later platinum-based therapy (median progression-free survival [mPFS]: 7.6 months). Second-line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable.
CONCLUSION: Eribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.